Key features and details
- Rabbit polyclonal to Topoisomerase I - C-terminal
- Suitable for: WB
- Reacts with: Human
- Isotype: IgG
Product nameAnti-Topoisomerase I antibody - C-terminal
See all Topoisomerase I primary antibodies
DescriptionRabbit polyclonal to Topoisomerase I - C-terminal
Tested applicationsSuitable for: WBmore details
Species reactivityReacts with: Human
Predicted to work with: Cow, Rhesus monkey
Synthetic peptide within Human Topoisomerase I (C terminal). The exact sequence is proprietary. Carrier-protein conjugated.
Database link: P11387
- WB: HEK-293T whole cell and nuclear extracts.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.00
Preservative: 0.025% Proclin 300
Constituents: 79% PBS, 20% Glycerol (glycerin, glycerine)
Concentration information loading...
PurityImmunogen affinity purified
Our Abpromise guarantee covers the use of ab227596 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/500 - 1/3000. Predicted molecular weight: 91 kDa.|
FunctionThe reaction catalyzed by topoisomerases leads to the conversion of one topological isomer of DNA to another.
Involvement in diseaseNote=A chromosomal aberration involving TOP1 is found in a form of therapy-related myelodysplastic syndrome. Translocation t(11;20)(p15;q11) with NUP98.
Sequence similaritiesBelongs to the eukaryotic type I topoisomerase family.
modificationsSumoylated. Lys-117 is the main site of sumoylation. Sumoylation plays a role in partitioning TOP1 between nucleoli and nucleoplasm. Levels are dramatically increased on camptothecin (CPT) treatment.
Cellular localizationNucleus > nucleolus. Nucleus > nucleoplasm. Diffuse nuclear localization with some enrichment in nucleoli. On CPT treatment, cleared from nucleoli into nucleoplasm. Sumolyated forms found in both nucleoplasm and nucleoli.
- Information by UniProt
- DNA topoisomerase 1 antibody
- DNA topoisomerase I antibody
- NUP98 fusion gene antibody
All lanes : Anti-Topoisomerase I antibody - C-terminal (ab227596) at 1/2000 dilution
Lane 1 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) whole cell extract
Lane 2 : HEK-293T (human epithelial cell line from embryonic kidney transformed with large T antigen) nuclear extract
Lysates/proteins at 5 µg per lane.
Predicted band size: 91 kDa
7.5% SDS-PAGE gel.
To our knowledge, customised protocols are not required for this product. Please try the standard protocols listed below and let us know how you get on.
ab227596 has not yet been referenced specifically in any publications.